Opinion|Videos|January 19, 2026
Potential Triplet Strategies in KMT2A+ AML
Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, discuss potential triplet strategies with menin inhibitors for KMT2A-rearranged AML.
Advertisement
Episodes in this series
Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, explore emerging triplet strategies incorporating menin inhibitors for patients with KMT2A-rearranged acute myeloid leukemia (AML). They review the biological rationale for targeting menin and how these agents may synergize with established backbones such as venetoclax (Venclexta)-based regimens. DiNardo and Altman discuss how these combinations could address historically poor outcomes in this high-risk population.
Advertisement
Related to this article
A prespecified analysis showed benefit with anselamimab in patients with kappa light chain AL amyloidosis.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The selective BCR::ABL1 inhibitor ELVN-001 produced major molecular responses in previously treated chronic-phase CML, including after asciminib progression.
Actinomycin D plus low-dose cytarabine and venetoclax produced high remission rates in a retrospective cohort of patients with NPM1-mutated AML.
Revumenib added to intensive chemotherapy produced deep, MRD-negative remissions with a manageable safety profile in newly diagnosed AML.
Ofirnoflast produced hematologic improvement in two-thirds of patients with ESA-refractory lower-risk MDS.
Mayo Clinic researchers identified a potential new approach to treating glioblastoma to improve the effectiveness of existing chemotherapy.
In the phase 2 RESTORE-PV trial, DISC-3405 cut phlebotomy events and maintained hematocrit below 45% in patients with polycythemia vera.
Advertisement
Advertisement
Trending on OncLive
1
Ofirnoflast Elicits Durable Transfusion Independence, Hematologic Improvement in Lower-Risk MDS
2
ACTIVE Regimen Elicits High Response Rates in R/R NPM1-Mutated AML
3
Revumenib Plus Chemo Yields High Response and MRD-Negativity Rates in Newly Diagnosed NPM1+ or KMT2A+ AML
4
Dr Gangat on Phase 2 Efficacy and Safety Data for DISC-3405 in Polycythemia Vera
5